A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab ( Anti‐CD20 ) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma
| Autor: | Darrell R. Fisher, Damian J. Green, Victor A. Chow, Joseph G. Rajendran, John M. Pagel, Ted Gooley, Ryan D. Cassaday, Oliver W. Press, Frederick R. Appelbaum, Ajay K. Gopal, Leona Holmberg, Philip A. Stevenson, Paul S. Martin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry medicine.medical_treatment Aggressive lymphoma Hematology medicine.disease Tositumomab Refractory Non-Hodgkin Lymphoma immune system diseases hemic and lymphatic diseases Internal medicine Radioimmunotherapy medicine Autologous transplantation Mantle cell lymphoma Progression-free survival business Etoposide medicine.drug |
| Zdroj: | American Journal of Hematology. 95:775-783 |
| ISSN: | 1096-8652 0361-8609 |
| Popis: | Radiation is the most effective treatment for localized lymphoma, but treatment of multifocal disease is limited by toxicity. Radioimmunotherapy (RIT) delivers tumoricidal radiation to multifocal sites, further augmenting response by dose-escalation. This phase II trial evaluated high-dose RIT and chemotherapy prior to autologous stem-cell transplant (ASCT) for high-risk, relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). The primary endpoint was progression free survival (PFS). Secondary endpoints were overall survival (OS), toxicity, and tolerability. Patients age |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text